BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025

Month

• January
• February
• March
• April
• May
• June
• July
• August
• September
• October
• November
• December

Day

• 1
• 2
• 3
• 4
• 5
• 6
• 7
• 8
• 9
• 10
• 11
• 12
• 13
• 14
• 15
• 16
• 18
• 19
• 20
• 21
• 22
• 23
• 24
• 25
• 26
• 27
• 28
• 29
• 30

• Biotech Bay

  Pliant Therapeutics to Participate in Needham Healthcare Conference

  Pliant Therapeutics, Inc. announced that Bernard Coulie, M.D., Ph.D., Pliant’s President and Chief Executive Officer, will participate in a fireside chat as part of the 21st Annual Needham Virtual Healthcare Conference on Tuesday, April 12, 2022, at 2:15 p.m. ET.

  April 5, 2022

   · 

  1 min read
• Drug Development

  Mersana Therapeutics to Present Preclinical Data on XMT-1660, XMT-2056 and the Immunosynthen Platform at AACR Annual Meeting

  Mersana Therapeutics, Inc. today announced that it will present three posters highlighting data for XMT-1660, XMT-2056, and the Immunosynthen ADC platform at the upcoming American Association for Cancer Research (AACR) Annual Meeting 2022 to be held in New Orleans, Louisiana from April 8-13, 2022.

  April 5, 2022

   · 

  7 min read
• Business

  OncoHost Announces Clinical Trial Collaboration with Roswell Park Comprehensive Cancer Center to Analyze Immunotherapy Resistance

  OncoHost announced today that Roswell Park Comprehensive Cancer Center has joined its PROPHETIC study, launching a clinical site in Buffalo, New York.

  April 5, 2022

   · 

  3 min read
• Drug Development

  Vaxess Announces Production of The First GMP Batch of MIMIX™ Technology Vaccine Patches for an Upcoming Phase 1 Seasonal Influenza Clinical Trial

  Vaxess Technologies announced significant progress towards clinical entry for the company’s lead program, MIMIX-Flu.

  April 5, 2022

   · 

  3 min read
• Business

  858 Therapeutics Expands Board of Directors and Leadership Team

  858 Therapeutics today announced the strengthening of its board of directors and leadership team in preparation for its next stage of growth.

  April 5, 2022

   · 

  3 min read
• Biotech Bay

  Agilent Companion Diagnostic Expands CE-IVD Mark for PD-L1 IHC 28-8 pharmDx to Include Esophageal Squamous Cell Carcinoma

  Agilent Companion Diagnostic Expands CE-IVD Mark for PD-L1 IHC 28-8 pharmDx to Include Esophageal Squamous Cell Carcinoma.

  April 5, 2022

   · 

  3 min read
• Biotech Bay

  Agilent Companion Diagnostic Expands CE-IVD Mark for PD-L1 IHC 28-8 pharmDx to Include Muscle-Invasive Urothelial Carcinoma (MIUC)

  Agilent Technologies Inc. (NYSE: A) today announced CE-IVD marking in the European Union for its PD-L1 IHC 28-8 pharmDx immunohistochemical assay to extend the use of the test to patients diagnosed with muscle-invasive urothelial carcinoma (MIUC).

  April 5, 2022

   · 

  2 min read
• Biotech Bay

  Vaxcyte to Present at the 21st Annual Needham Virtual Healthcare Conference

  Vaxcyte, Inc. today announced that Company management will participate in a fireside chat at the 21st Annual Needham Virtual Healthcare Conference on Tuesday, April 12, 2022 at 12:45 p.m. ET.

  April 5, 2022

   · 

  1 min read
• BioMidwest

  Baxter Announces U.S. FDA Clearance of ST Set Used to Help Treat Acute Kidney Injury Patients in the Hospital

  Baxter International Inc. (NYSE:BAX), a global leader in acute care, today announced the U.S. Food and Drug Administration (FDA) 510(k) clearance of the company’s ST Set used in continuous renal replacement therapy (CRRT).

  April 5, 2022

   · 

  5 min read
• Biotech Beach

  ImmixBio Management Discusses Key Milestones, Drug Development Timelines and the IMMX Advantage at IMMX Milestone Day Event Held on April 5, 2022

  Immix Biopharma, Inc. announced that management discussed key milestones, drug development timelines and the IMMX Advantage at its Milestone Day Event held at 9:30am ET on April 5, 2022.

  April 5, 2022

   · 

  4 min read